Advertisement
ANIK vs ORGO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a StrongBuy and ORGO is a Hold.
ANIK's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ANIK turned positive on October 13, 2026. Looking at past instances where ANIK's MACD turned positive, the stock continued to rise in 37 of 52 cases over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANIK's RSI Oscillator exited the oversold zone, 15 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 47%.
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on ANIK as a result. In 77 of 114 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
ANIK moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIK advanced for three days, in 167 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
ANIK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ANIK crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for ANIK entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.056) is normal, around the industry mean (10.407). P/E Ratio (-78.111) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (2.177) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.401) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ANIK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Momentum Indicator for ORGO turns negative, indicating new downward trend
ORGO saw its Momentum Indicator move below the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 76 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ORGO turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 39 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ORGO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
ORGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.860) is normal, around the industry mean (11.138). P/E Ratio (-1.271) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.404) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ORGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
ANIK | ORGO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 91 | 98 | |
PRICE GROWTH RATING 1..100 | 36 | 92 | |
P/E GROWTH RATING 1..100 | 100 | 97 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANIK's Valuation (10) in the Pharmaceuticals Other industry is in the same range as ORGO (37) in the Financial Conglomerates industry. This means that ANIK’s stock grew similarly to ORGO’s over the last 12 months.
ANIK's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ORGO (100) in the Financial Conglomerates industry. This means that ANIK’s stock grew similarly to ORGO’s over the last 12 months.
ANIK's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as ORGO (98) in the Financial Conglomerates industry. This means that ANIK’s stock grew similarly to ORGO’s over the last 12 months.
ANIK's Price Growth Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for ORGO (92) in the Financial Conglomerates industry. This means that ANIK’s stock grew somewhat faster than ORGO’s over the last 12 months.
ORGO's P/E Growth Rating (97) in the Financial Conglomerates industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.
| ANIK | ORGO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 47% | 2 days ago 79% |
| Stochastic ODDS (%) | 1 day ago 69% | 2 days ago 79% |
| Momentum ODDS (%) | 1 day ago 68% | 2 days ago 90% |
| MACD ODDS (%) | 1 day ago 71% | 2 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 68% | 2 days ago 90% |
| TrendMonth ODDS (%) | 1 day ago 73% | 2 days ago 89% |
| Advances ODDS (%) | 1 day ago 63% | N/A |
| Declines ODDS (%) | 21 days ago 68% | 7 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 63% | 2 days ago 76% |
| Aroon ODDS (%) | 1 day ago 73% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANIK’s FA Score shows that 1 FA rating(s) are green while ORGO’s FA Score has 0 green FA rating(s).
- ANIK’s FA Score: 1 green, 4 red.
- ORGO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANIK’s TA Score shows that 5 TA indicator(s) are bullish while ORGO’s TA Score has 3 bullish TA indicator(s).
- ANIK’s TA Score: 5 bullish, 5 bearish.
- ORGO’s TA Score: 3 bullish, 4 bearish.
Price Growth
ANIK (@Pharmaceuticals: Generic) experienced а +1.73% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was -13.04% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
ANIK is expected to report earnings on Nov 04, 2026.
ORGO is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ANIK and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with RVTY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then RVTY could also see price increases.
| Ticker / NAME | Correlation To ANIK | 1D Price Change % | ||
|---|---|---|---|---|
| ANIK | 100% | +2.38% | ||
| RVTY - ANIK | 39% Loosely correlated | +0.48% | ||
| ORGO - ANIK | 36% Loosely correlated | +3.90% | ||
| ACRS - ANIK | 34% Loosely correlated | +0.52% | ||
| FLGT - ANIK | 32% Poorly correlated | -0.70% | ||
| INFU - ANIK | 32% Poorly correlated | +0.64% | ||
More | ||||
ORGO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIK. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIK could also see price increases.
| Ticker / NAME | Correlation To ORGO | 1D Price Change % | ||
|---|---|---|---|---|
| ORGO | 100% | -2.81% | ||
| ANIK - ORGO | 36% Loosely correlated | +0.78% | ||
| PRGO - ORGO | 31% Poorly correlated | -1.61% | ||
| ACET - ORGO | 29% Poorly correlated | -0.66% | ||
| IRWD - ORGO | 23% Poorly correlated | -2.20% | ||
| AMPH - ORGO | 23% Poorly correlated | +1.00% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FXU | 47.83 | 1.01 | +2.16% |
| First Trust Utilities AlphaDEX Fund (FXU) | |||
| BSMV | 20.22 | 0.05 | +0.23% |
| Invesco BulletShares 2031 Municipal Bond ETF (BSMV) | |||
| XBOC | 36.49 | -0.26 | -0.70% |
| Innovator U.S. Equity Accelerated 9 Buffer ETF - October (XBOC) | |||
| CGUS | 44.37 | -0.67 | -1.49% |
| Capital Group Core Equity ETF (CGUS) | |||
| TEKX | 48.70 | -3.41 | -6.54% |
| State Street Galaxy Transformative Tech Accelerators ETF (TEKX) | |||